SP94
SP94 is a peptide ligand with high specificity for hepatocellular carcinoma cells. SP94 selectively binds to multiple hepatocellular carcinoma cell lines in vitro. SP94 inhibits tumor growth in a mouse model of hepatocellular carcinoma by promoting apoptosis and reducing angiogenesis. SP94 can be used as a specific probe for hepatocellular carcinoma imaging. SP94 is useful for hepatocellular carcinoma research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1158983-49-3
- Formule: C65H104N14O16
- Masse moléculaire:1337.61
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
SP94 (40 nM of HspG41C-SM(PEG)n-SP94, 12/23 peptides/cage, 24 h) could bind selectively to HepG2 and Huh-7 cells, but does not bind to HeLa and RLN-8 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 and Huh-7 cells
-
Concentration:40 nM of HspG41C-SM(PEG)n-SP94, 12/23 peptides/cage
-
Incubation Time:24 h
-
Result:Induced Alexa488 green fluorescence, increased the binding of conjugates with increasing SP94 peptide numbers on liposomes.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mahlavu cells (5x106) xenograft severe combined immunodeficient mice (4-6 weeks old) model[1]
-
Dosage:100 µg + PC94
-
Administration:once
-
Result:Inhibited recovery of phage particle from tumor tissue, inhibited 88% of PC94 binding to tumor tissue.
-
Animal Model:Mahlavu cells (5x106) xenograft severe combined immunodeficient mice (4-6 weeks old) model[1]
-
Dosage:1 mg/kg, with PEGylated liposomal Doxorubicin (HY-15142A) (SP94-LD).
-
Administration:i.v., twice a week, for 4 consecutive weeks
-
Result:Reduced the tumor size and weight, with 40% inhibition compared with that in the CP-LD- and LD-treated groups.
Increased the total WBC count, did not change body weight.
Showed marked disseminated necrotic/apoptotic areas, increased apoptotic tumor cells, decreased the density of blood vessels.
-
Animal Model:Mahlavu cells (5x106) xenograft severe combined immunodeficient mice (4-6 weeks old) model[1]
-
Dosage:5 mg/kg, with PEGylated liposomal Doxorubicin (SP94-LD).
-
Administration:i.v., once a week, for 2 consecutive weeks
-
Result:Reduced the tumor size and weight, increased the total WBC count, showed marked disseminated necrotic/apoptotic areas, areas of CD31+ endothelial cells, decreased areas of CD31+ endothelial cells.
Chemical Information
-
CAS No. 1158983-49-3
-
Masse moléculaire 1337.61
-
Formule C65H104N14O16
-
Sequence
Ser-Phe-Ser-Ile-Ile-His-Thr-Pro-Ile-Leu-Pro-Leu
-
Sequence Shortening
SFSIIHTPILPL
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Lo A, et al. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther. 2008 Mar;7(3):579-89. [Content Brief]
[2]. Toita R, et al. Development of human hepatocellular carcinoma cell-targeted protein cages. Bioconjug Chem. 2012 Jul 18;23(7):1494-501. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SP94 Related Classifications
HY-P11050A Related Classifications
Powered by Bioz